On 2014 Jul 13, Jorge H Ramírez commented:

PubMed Commons comment

I would like to make the following remarks about this study.

• The sample size (n=383567) and time of patient follow-up (16 weeks, interquartile range 5-50 weeks) of Bird ST, 2013 study is clearly superior to the registered (published and unpublished) previous studies of tamsulosin (n=83201; median time of follow-up=6 weeks, interquartile range 2-12 weeks).1,2

• "The available scientific evidence supports the association of tamsulosin with serious adverse cardiovascular drug reactions, probably more than any other pharmacological effect attributed to this drug. I urge doctors to reconsider the use of tamsulosin as a first line treatment in patients with lower urinary tract symptoms."1

• Tamsulosin is not uroselective.1,2

• Over three quarters of tamsulosin studies are unpublished.1,2

References

1. Ramirez JH. Re: Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology (May 16, 2014) http://www.bmj.com/content/347/bmj.f6320/rr/698284

2. Ramirez, Jorge H (2014): Expression of concern about tamsulosin: over three quarters of human studies are unpublished. figshare. http://dx.doi.org/10.6084/m9.figshare.1094338

On 2014 Jul 13, Jorge H Ramírez commented:

PubMed Commons comment

I would like to make the following remarks about this study.

• The sample size (n=383567) and time of patient follow-up (16 weeks, interquartile range 5-50 weeks) of Bird ST, 2013 study is clearly superior to the registered (published and unpublished) previous studies of tamsulosin (n=83201; median time of follow-up=6 weeks, interquartile range 2-12 weeks).1,2

• "The available scientific evidence supports the association of tamsulosin with serious adverse cardiovascular drug reactions, probably more than any other pharmacological effect attributed to this drug. I urge doctors to reconsider the use of tamsulosin as a first line treatment in patients with lower urinary tract symptoms."1

• Tamsulosin is not uroselective.1,2

• Over three quarters of tamsulosin studies are unpublished.1,2

References

1. Ramirez JH. Re: Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology (May 16, 2014) http://www.bmj.com/content/347/bmj.f6320/rr/698284

2. Ramirez, Jorge H (2014): Expression of concern about tamsulosin: over three quarters of human studies are unpublished. figshare. http://dx.doi.org/10.6084/m9.figshare.1094338